HDAC inhibitors (HDACi) are novel drugs for tumor-targeted therapy that inhibit tumor cell proliferation and induce cell differentiation or apoptosis by increasing the acetylation level of intracellular histones (Manal et al., 2016; Eckschlager et al., 2017). Here, HDAC9 is linked to neoplasm.